SynthesisWorld journal of gastroenterology2016
Systematic review of prognostic importance of extramural venous invasion in rectal cancer.
Synthesis in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- PET/MRI and PET/CT hybrid imaging of rectal cancer - description and initial observations from the RECTOPET (REctal Cancer trial on PET/MRI/CT) study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2019Trial
- MRI-Based Morphological Features as Predictors of Clinical Outcomes in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy: Insights from a Single-Institution Experience.Journal of clinical medicine · 2026Article
- D3 lymph node dissection in right-sided colon cancer: routine requirement or selective application?Journal of gastrointestinal oncology · 2025Article
- MRI for Rectal Cancer: Updates and Controversies-AJR. American journal of roentgenology · 2025Review
- Article
- Diagnostic Certainty in Characterizing Liver Lesions in Rectal Cancer: Abbreviated Liver MRI versus CT.Annals of surgical oncology · 2025Article
- Review
- Colorectal Cancer: A Brief and Simplified Analysis of a Complex Disease.Medicina (Kaunas, Lithuania) · 2024Article
- The Role of Predictive and Prognostic MRI-Based Biomarkers in the Era of Total Neoadjuvant Treatment in Rectal Cancer.Cancers · 2024Review
- Double Negativity of MRI-Detected and Pathologically-Diagnosed Extramural Venous Invasion is a Favorable Prognostic Factor for Rectal Cancer.Annals of surgical oncology · 2024Article
- Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II-III Colorectal Cancer: A Population-based Study.Cancer research communications · 2024Article
- Risk Factors for Distant Metastasis in T3 T4 Rectal Cancer.Clinical Medicine Insights. Oncology · 2024Article
- Long-term outcomes of upfront robotic rectal cancer surgery: a single-center, retrospective cohort study in Japan.Surgery today · 2023Article
- Extramural Venous Invasion and Tumor Deposit at Diffusion-weighted MRI in Patients after Neoadjuvant Treatment for Rectal Cancer.Radiology · 2023Article
- Quantitative assessment of the microstructure of the mesorectum with different prognostic statuses by intravoxel incoherent motion diffusion-weighed magnetic resonance imaging.BMC gastroenterology · 2022Article
- Extramural venous invasion and depth of extramural invasion on preoperative CT as prognostic imaging biomarkers in patients with locally advanced ascending colon cancer.Abdominal radiology (New York) · 2022Article
- T-stage downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy is not associated with reduced recurrence after adjusting for tumour characteristics.Journal of surgical oncology · 2022Article
- Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Preoperative prediction of extramural venous invasion in rectal cancer by dynamic contrast-enhanced and diffusion weighted MRI: a preliminary study.BMC medical imaging · 2022Article
- Development of an Online Curriculum for Surgeons on the Use of Pelvic Magnetic Resonance Imaging in Rectal Cancer and Results of a Pilot Study.The Journal of surgical research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo systematically review the survival outcomes relating to extramural venous invasion in rectal cancer.
methodsA systematic review was conducted using PRISMA guidelines. An electronic search was carried out using MEDLINE, EMBASE, CINAHL, Cochrane library databases, Google scholar and PubMed until October 2014. Search terms were used in combination to yield articles on extramural venous invasion in rectal cancer. Outcome measures included prevalence and 5-year survival rates. These were graphically displayed using Forest plots. Statistical analysis of the data was carried out.
resultsFourteen studies reported the prevalence of extramural venous invasion (EMVI) positive patients. Prevalence ranged from 9%-61%. The pooled prevalence of EMVI positivity was 26% [Random effects: Event rate 0.26 (0.18, 0.36)]. Most studies showed that EMVI related to worse oncological outcomes. The pooled overall survival was 39.5% [Random effects: Event rate 0.395 (0.29, 0.51)].
conclusionHistorically, there has been huge variation in the prevalence of EMVI through inconsistent reporting. However the presence of EMVI clearly leads to worse survival outcomes. As detection rates become more consistent, EMVI may be considered as part of risk-stratification in rectal cancer. Standardised histopathological definitions and the use of magnetic resonance imaging to identify EMVI will improve detection rates in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.